Lucid Group Appoints Former Pfizer R&D Leader Rod MacKenzie, CMG, PhD, as Board Chair to Drive Next Phase of Global Growth and Innovation
March 18, 2026 |
Appointment marks a pivotal step in Lucid’s next phase of growth, strengthening its ability to translate complex science into real-world impact.
Lucid’s US Medical Affairs division unveils new proprietary insights tools to expand advisory capabilities.
LONDON & PHILADELPHIA, March 18, 2026 – Lucid Group, a global leader in healthcare communications and commercialisation, today announced that Rod MacKenzie, CMG, PhD, former Executive Vice President and Chief Development Officer at Pfizer, has been appointed as the new Chair of the Lucid Group Board of Directors. Dr MacKenzie will succeed Andy Black, who retired from the Board following the end of his term.
This appointment reflects a shared mission with Lucid Group to transform lives by ensuring innovative medicine doesn’t stop at approval but reaches the patients who need it most. His leadership marks a pivotal step in Lucid’s next phase of growth, strengthening its ability to translate complex science into real-world impact.
“Dr MacKenzie’s career is defined by his dedication to patient outcomes and a deep understanding that breakthrough science only matters when translated into action,” said Rick Sannem, CEO of Lucid Group. “His arrival supports our shared vision that we don’t just help clients talk about their science, we uncover the defining insights that shape behaviour so life-changing medicines find their rightful place in the market.”
Dr MacKenzie spent 34 years at Pfizer, where he led the Global Product Development division and oversaw 6,000 professionals dedicated to advancing innovative medicines and vaccines. He played a critical role in the development of both the Pfizer-BioNTech COVID-19 vaccine and antiviral, Paxlovid, in addition to serving on Pfizer’s Executive Leadership Team from 2016 to 2022. In recognition of his contributions to public health during the pandemic, he was appointed Companion of the Order of St Michael and St George by Queen Elizabeth II in 2022.
“Inventing and developing innovative medicines takes great science and execution. But translating that science into improved patient outcomes in clinical practice requires real strategic discipline,” said Dr MacKenzie. “Even brilliant science can struggle to break through, so innovative companies need a strategic partner like Lucid, whose integrated approach to solving complex challenges delivers changes in behaviours that successfully overcome treatment barriers. Lucid’s cre
ativity and unique data synthesis capabilities really stand out in the marketplace. I am thrilled to join the Lucid Board and share Lucid’s deep commitment to transforming lives across the globe.”
In addition to Dr MacKenzie’s appointment, Lucid’s US Medical Affairs division is unveiling new proprietary insights tools to expand its advisory capabilities at the Medical Affairs Professional Society (MAPS) conference in Denver from 22-25 March:
- Influence Amplifier™ – Closes the gap between communication and behaviour change by combining real-time behavioural insights, precision targeting, and adaptive analytics to expand peer-to-peer communication relevance and audience priorities.
- Impact Validator™ – Pinpoints precisely where efforts drive change through a five-step framework spanning clinical gaps and audience priorities, tailored interventions, omnichannel engagement, performance data, and adaptive refinement.
Together, these tools magnify and document scientific impact while delivering Precision Engagement™, a repeatable, self‑optimising cycle that continuously strengthens scientific influence, impact, and patient outcomes over time.
To demonstrate how Lucid Medical is enabling Medical Affairs teams to be strategic catalysts for change, it is offering free, 30-minute Impact Calibration™ sessions designed to map Medical Affairs teams’ current influence and spotlight opportunities for measurable growth.
About Lucid Group
Lucid Group, a global leader in healthcare communications and commercialisation, is driven by a mission to transform lives by bridging the gap between scientific discovery and patient impact. For life sciences organisations navigating their highest-stakes decisions, Lucid doesn’t just communicate science but ensures clients leave a lasting impact on the market and the patients they serve. Lucid brings together experts across Strategy Consulting, Scientific and Medical Communications, and Commercial Communications, fusing scientific rigour, strategic foresight, commercial ingenuity, creative storytelling, and deep human insight into an integrated force, powered by real-world evidence. This unique approach allows Lucid to uncover the ‘Lucid Truth’— the deep-seated insight that governs stakeholder behaviour and anchors bold, behaviour-changing ideas, executed at key moments and accelerated by AI and technology. To learn more about Lucid Group, visit www.wearelucidgroup.com and LinkedIn.
Media Contacts:
Chris Dougherty
CDougherty@reboundb2b.com
Elyse Cole
media@wearelucidgroup.com
This content was provided by Lucid Group Communications Limited
Company Details
Latest Content from Lucid Group Communications Limited
Lucid Group tough it out with a weekend full of charity challenges
This weekend the Lucid charity working group, Lucid SPIRIT, took on two separate challenges to help raise funds for the Wycombe Homeless Connection and Children in Need.On Saturday seventeen Lucidians...
#LucidLife is just about to get better with the move to Middlesex House
With only a few weeks to go Jan Steele, Lucid co-founder and COO discusses how the move to Middlesex House supports its commitment to making Lucid a great place to...
Lucid Group has four programmes shortlisted for PMEA 2019
Lucid is celebrating four of their programmes being shortlisted in four categories at this year's PMEAs
The heart of Lucid’s new HQ is under construction
With just 3 weeks until the move, the new kitchen and bar are being installed in Middlesex House.
Bluedog boosts its senior team with the appointment of its new Technical Director
Bluedog, a Lucid Group company, is set to create more magic for its clients with the appointment of Jonathan Andrew as its new technical director.Jonathan has a proven track record...
HealthCare21 experience the Lucid magic at its Engagement Day
Yesterday was a big step forward in the integration of HealthCare21 into Lucid Group. Everyone from the HealthCare21 team attended the Engagement Day at Quarry House Mill, Macclesfield.The aim was to...
Lucid Group start the countdown to its big move
One month to go until Lucid Group moves into their new London Headquarters
Lucid Group increases footprint in UK, Asia Pacific and Middle East with the acquisition of HealthCare21
Lucid Group is delighted to announce its latest acquisition, welcoming colleagues from Healthcare consultancy HealthCare21 into its magic kingdom.Over the last twelve years, Lucid Group has become well known and...
Lucid Group Lucky Lunches prove a spellbinding hit this summer
Lucid Group Lucky Lunches have been running throughout the summer months, giving our teams the chance to network and connect outside of the office - as well as enjoying a...
Lucid’s Summer Fridays Shone
Lucid Group has been enjoying long weekends throughout the summer thanks to Summer Fridays, a concept introduced in line with Lucid’s agile working policy.Employees have been encouraged to spread their...